LY-393558 Structure.svg
  • 1-(2-(4-(6-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)ethyl)-3-isopropyl-6-(methylsulfonyl)-3,4-dihydro-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass546.68 g·mol−1
3D model (JSmol)
  • FC1=CC=C2C(NC=C2C3=CCN(CCN4S(N(C(C)C)CC5=C4C=CC(S(=O)(C)=O)=C5)(=O)=O)CC3)=C1
  • InChI=1S/C26H31FN4O4S2/c1-18(2)31-17-20-14-22(36(3,32)33)5-7-26(20)30(37(31,34)35)13-12-29-10-8-19(9-11-29)24-16-28-25-15-21(27)4-6-23(24)25/h4-8,14-16,18,28H,9-13,17H2,1-3H3

LY-393558 is a potent serotonin reuptake inhibitor and antagonist of the 5-HT1B, 5-HT1D, and 5-HT2A receptors. LY-393558 was also found to reduce serotonin-induced vasoconstriction, indicating that it may have therapeutic potential for the treatment of pulmonary hypertension.[1][2]


  1. ^ Mitchell SN, Greenslade RG, Cooper J (November 2001). "LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat". European Journal of Pharmacology. 432 (1): 19–27. doi:10.1016/S0014-2999(01)01469-8. PMID 11734183.
  2. ^ Baranowska-Kuczko M, Kozłowska H, Schlicker E, Göthert M, MacLean MR, Kozłowski M, et al. (June 2020). "Reduction of the serotonin 5-HT1B and 5-HT2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT1B receptor antagonist and serotonin transporter inhibitor LY393558". Pharmacological Reports. 72 (3): 756–762. doi:10.1007/s43440-020-00105-2. PMC 7329800. PMID 32333296.